Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based biotechnology company 4-Antibody has appointed Richard Mason as its new CEO. Dr Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an executive-in-residence.
Subscribe to our email newsletter
Previously Dr Mason was senior vice president of business development at Cambridge Antibody Technology. Dr Mason holds a BSc degree in immunology from University College London and an MBA from the Judge Business School, University of Cambridge.
Max Burger, chairman of 4-Antibody’s board, said: “We are delighted to appoint Richard as our CEO to lead 4-Antibody through the next exciting phase of its growth. His organizational leadership skills and experience in commercial dealmaking in the antibody space will be instrumental as we establish our technology as a new goldstandard for the discovery of fully human monoclonal antibody therapeutics.”